서울제약

018680KOSDAQ의약품 제조업

38.0 / 100

Reference Date: 2026-04-13

Financial Score7.5 / 40

News Sentiment12.5 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is undervalued vs. peers but the high debt ratio poses financial risk. Slightly up 3.2% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Seoul Pharmaceutical focuses on developing improved new drugs and innovative drug delivery technologies, such as SmartFilm® Technology, to maintain competitiveness in the global pharmaceutical market. Key products like Ator, a cholesterol-lowering medication, drive growth, with sales reaching 53,580 million KRW and operating profit increasing by 26% in 2024. The company is expanding its market share in chronic disease areas and preparing to launch first-generic products ahead of patent expirations.

Number of Employees

132people

Average Salary

65.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

42.54Industry Average 14.800.0Point

2.9x industry avg (risky)

PBR

0.79Industry Average 1.044.0Point

In line with industry avg

ROE

1.86Industry Average 4.421.0Point

Well below industry avg

Debt Ratio

38.51Industry Average 11.980.0Point

3.2x industry avg (risky)

Trend 2023~20252.5 / 10 points

Revenue Growth Rate

0.5 / 3

Avg ▼0.3% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼78.9% (2-year basis)

ROE Trend

2.0 / 4

Avg ROE 5.2% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (25%)

Current 2,765Won52-week high 3,83552-week low 2,400

1-month return4.0Point

1m +3.17% (slight rise)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

6 totalPositive 0Neutral 6Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-04-01
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-27
Neutral정기주주총회결과2026-03-27
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-27
Neutral감사보고서제출2026-03-19